{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["CF_EN"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CF_EN","index":0,"n_rows":49,"n_cols":4,"rows_kept":49,"cut":false,"hidden":false,"merged":[[2,1,2,2],[1,1,1,2]]}
[null,"Consolidated statement of cash flows (IFRS)"]
[null,"from 1 October 2017 to 31 March 2017"]
[]
[null,null,"2017/18\n1 Oct 17 to 31 Mar 18","2016/17\n1 Oct 16 to 31 Mar 17"]
[null,null,"€ k","€ k"]
[null,"Cash flows from operating activities:"]
[null,"Consolidated profit",56293,63825]
[null,"Adjustments to reconcile consolidated profit to net cash \nprovided by / (used in) operating activities"]
[null,"Income taxes",27652,29147]
[null,"Interest income / expenses",1139,743]
[null,"Result from disposal of legal entity / hydrophilic IOL business Aaren Scientific Inc.",-2499,-7721]
[null,"Depreciation and amortisation",13076,11186]
[null,"Gains / losses on disposal of fixed assets ",1763,-18]
[null,"Interest received",366,384]
[null,"Interest paid",-1161,-707]
[null,"Refunded income taxes",519,5476]
[null,"Income taxes paid",-26200,-33875]
[null,"Changes in working capital:"]
[null,"Trade receivables",-14826,-24419]
[null,"Inventories",-18883,-18559]
[null,"Other assets",17183,1355]
[null,"Trade payables",-14147,-92]
[null,"Provisions and financial liabilities",-6072,-5896]
[null,"Other liabilities",159,-4340]
[null,"Total adjustments",-21931,-47336]
[null,"Net cash provided by / (used in) operating activities",34362,16489]
[null,"Cash flows from investing activities::"]
[null,"Investment in property, plant and equipment",-6652,-5974]
[null,"Investment in other intangible assets",-6897,-7657]
[null,"Proceeds from fixed assets",205,224]
[null,"Payments for other loans",0,-2400]
[null,"Investment/ divestment in securities",1855,0]
[null,"Purchase of shares in affiliated non-consolidated companies",0,-13572.306819256599]
[null,"Proceeds from disposal of legal entity / hydrophilic IOL business Aaren Scientific Inc.",2548,9289]
[null,"Net cash provided by / (used in) investing activities",-8941,-20090.306819256599]
[null,"Cash flows from financing activities:"]
[null,"Proceeds from / (repayment of) current liabilities to banks",-72,-193]
[null,"Proceeds from / (repayment of) non-current liabilities to banks",-247,-343]
[null,"(Increase) / decrease in treasury receivables",22054,-322769]
[null,"Increase / (decrease) in treasury payables",-38361,14449]
[null,"Increase / (decrease) in liabilities due to finance lease",-1384,-1499]
[null,"Dividend payments to non-controlling interests",-5551,0]
[null,"Proceeds from capital increase (net)",0,315036.48448799993]
[null,"Net cash provided by / (used in) financing activities",-18010,4681.4844879999291]
[null,"Effect of exchange rate fluctuation on cash and cash equivalents",-134,-482]
[null,"Net increase / (decrease)  in cash and cash equivalents",1726,598.17766874333029]
[null,"Cash and cash equivalents, beginning of reporting period",3925,8710]
[null,"Cash and cash equivalents, end of reporting period",5651,9308.1776687433303]
[null,"The following notes are an integral part of the unaudited consolidated financial statements."]